Cargando…
Cost of unintended pregnancy in Norway: a role for long-acting reversible contraception
OBJECTIVES: The objective of this study was to quantify the cost burden of unintended pregnancies (UPs) in Norway, and to estimate the proportion of costs due to imperfect contraceptive adherence. Potential cost savings that could arise from increased uptake of long-acting reversible contraception (...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4369438/ https://www.ncbi.nlm.nih.gov/pubmed/25537792 http://dx.doi.org/10.1136/jfprhc-2014-100878 |
_version_ | 1782362763243290624 |
---|---|
author | Henry, Nathaniel Schlueter, Max Lowin, Julia Lekander, Ingrid Filonenko, Anna Trussell, James Skjeldestad, Finn Egil |
author_facet | Henry, Nathaniel Schlueter, Max Lowin, Julia Lekander, Ingrid Filonenko, Anna Trussell, James Skjeldestad, Finn Egil |
author_sort | Henry, Nathaniel |
collection | PubMed |
description | OBJECTIVES: The objective of this study was to quantify the cost burden of unintended pregnancies (UPs) in Norway, and to estimate the proportion of costs due to imperfect contraceptive adherence. Potential cost savings that could arise from increased uptake of long-acting reversible contraception (LARC) were also investigated. METHODS: An economic model was constructed to estimate the total number of UPs and associated costs in women aged 15–24 years. Adherence-related UP was estimated using ‘perfect use’ and ‘typical use’ contraceptive failure rates. Potential savings from increased use of LARC were projected by comparing current costs to projected costs following a 5% increase in LARC uptake. RESULTS: Total costs from UP in women aged 15–24 years were estimated to be 164 million Norwegian Kroner (NOK), of which 81.7% were projected to be due to imperfect contraceptive adherence. A 5% increase in LARC uptake was estimated to generate cost savings of NOK 7.2 million in this group. CONCLUSIONS: The cost of UP in Norway is substantial, with a large proportion of this cost arising from imperfect contraceptive adherence. Increased LARC uptake may reduce the UP incidence and generate cost savings for both the health care payer and contraceptive user. |
format | Online Article Text |
id | pubmed-4369438 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-43694382015-04-13 Cost of unintended pregnancy in Norway: a role for long-acting reversible contraception Henry, Nathaniel Schlueter, Max Lowin, Julia Lekander, Ingrid Filonenko, Anna Trussell, James Skjeldestad, Finn Egil J Fam Plann Reprod Health Care Article OBJECTIVES: The objective of this study was to quantify the cost burden of unintended pregnancies (UPs) in Norway, and to estimate the proportion of costs due to imperfect contraceptive adherence. Potential cost savings that could arise from increased uptake of long-acting reversible contraception (LARC) were also investigated. METHODS: An economic model was constructed to estimate the total number of UPs and associated costs in women aged 15–24 years. Adherence-related UP was estimated using ‘perfect use’ and ‘typical use’ contraceptive failure rates. Potential savings from increased use of LARC were projected by comparing current costs to projected costs following a 5% increase in LARC uptake. RESULTS: Total costs from UP in women aged 15–24 years were estimated to be 164 million Norwegian Kroner (NOK), of which 81.7% were projected to be due to imperfect contraceptive adherence. A 5% increase in LARC uptake was estimated to generate cost savings of NOK 7.2 million in this group. CONCLUSIONS: The cost of UP in Norway is substantial, with a large proportion of this cost arising from imperfect contraceptive adherence. Increased LARC uptake may reduce the UP incidence and generate cost savings for both the health care payer and contraceptive user. BMJ Publishing Group 2015-04 2014-12-23 /pmc/articles/PMC4369438/ /pubmed/25537792 http://dx.doi.org/10.1136/jfprhc-2014-100878 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/ |
spellingShingle | Article Henry, Nathaniel Schlueter, Max Lowin, Julia Lekander, Ingrid Filonenko, Anna Trussell, James Skjeldestad, Finn Egil Cost of unintended pregnancy in Norway: a role for long-acting reversible contraception |
title | Cost of unintended pregnancy in Norway: a role for long-acting reversible contraception |
title_full | Cost of unintended pregnancy in Norway: a role for long-acting reversible contraception |
title_fullStr | Cost of unintended pregnancy in Norway: a role for long-acting reversible contraception |
title_full_unstemmed | Cost of unintended pregnancy in Norway: a role for long-acting reversible contraception |
title_short | Cost of unintended pregnancy in Norway: a role for long-acting reversible contraception |
title_sort | cost of unintended pregnancy in norway: a role for long-acting reversible contraception |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4369438/ https://www.ncbi.nlm.nih.gov/pubmed/25537792 http://dx.doi.org/10.1136/jfprhc-2014-100878 |
work_keys_str_mv | AT henrynathaniel costofunintendedpregnancyinnorwayaroleforlongactingreversiblecontraception AT schluetermax costofunintendedpregnancyinnorwayaroleforlongactingreversiblecontraception AT lowinjulia costofunintendedpregnancyinnorwayaroleforlongactingreversiblecontraception AT lekanderingrid costofunintendedpregnancyinnorwayaroleforlongactingreversiblecontraception AT filonenkoanna costofunintendedpregnancyinnorwayaroleforlongactingreversiblecontraception AT trusselljames costofunintendedpregnancyinnorwayaroleforlongactingreversiblecontraception AT skjeldestadfinnegil costofunintendedpregnancyinnorwayaroleforlongactingreversiblecontraception |